AIDS Therapies

Comparing Lamivudine To Emtricitabine Influenced By Cell Line

Published in AIDS Weekly, August 13th, 2001

New research comparing the in vitro antiviral potency of Epivir^R (lamivudine or 3TC, GlaxoSmithKline) and emtricitabine or FTC contradicts earlier study results and found no significant difference between the two drugs when potency is compared in primary cell lines.

The new study was presented July 9, 2001, at the International AIDS Society (IAS) conference.

Epivir and emtricitabine (Triangle/Abbott) are structurally similar nucleoside reverse transcriptase inhibitors that previously have been compared in a limited number of in vitro studies. The study presented at the conference compared the two drugs using three different cell types,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-08-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry